Posts Tagged ‘australia’
Elite PR joins Global Health Marketing & Communications (GHMC) as exclusive Taiwanese agency
Taiwan-based communications agency, Elite PR, has this week joined the world’s largest, and most robust network of independent healthcare agencies – Global Health Marketing & Communications (GHMC). Bolstering GHMC’s capabilities and footprint in the Asia Pacific (APAC) region, Elite PR has an exemplary, 35+ year-strong record of experience in the Taiwanese health sector. Established in…
Read MoreCelebrating 30 years of the ‘JDRF One Walk’ for Type 1 diabetes
This October 2023, the Juvenile Diabetes Foundation (JDRF) is celebrating 30 years of running the JDRF local One Walk. Striving to achieve a world free from Type 1 diabetes (T1D) courtesy of crucial, life-changing research, the JDRF One Walk event provides invaluable support to the T1D community, including the more than 130,000 Australians living with…
Read MoreGlobal Health Marketing and Communications (GHMC) welcomes Improve Comunicaciones as an exclusive agency partner in Mexico, strengthening network’s capabilities in Latin America
As the exclusive Australian partner of Global Health Marketing and Communications (GHMC) – the largest and most robust network of independent healthcare agencies worldwide – VIVA! Communications extends a warm welcome to our newest member – Improve Comunicaciones. The addition of the Mexican-based, strategic consulting agency to GHMC, strengthens our GHMC network’s offering, and capabilities…
Read MoreVIVA! Communications clinches Best PR Campaign – Awareness and Advocacy with Edwards Lifesciences at the 2022 PRIME Awards
VIVA! Communications marked the 18th annual PRIME Awards in style last night (Thursday, November 10, 2022) together with our much-valued clientele, Edwards Lifesciences and Dr Falk Pharma, and Australian representatives from the pharmaceutical industry, at the Sofitel Wentworth Sydney Hotel. Hosted by comedian, musician and former member of ABC TV’s satirical program, The Chaser,…
Read MoreEpiPen supplies returning to normal after year-long shortage
Widespread shortages of EpiPen, an epinephrine autoinjector for the treatment of anaphylaxis, have been resolved. The Therapeutic Goods Administration (TGA) confirmed this week the supply had returned to normal following a worldwide shortage that lasted almost a year. Issues with overseas manufacturers of the Mylan product in April 2018 had international ramifications, forcing those with…
Read More